Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

Sponsor
Emory University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05378113
Collaborator
(none)
120
1
2
4
29.9

Study Details

Study Description

Brief Summary

This study is a randomized, single-site clinical trial that will take place at Children's Healthcare of Atlanta at Egleston. The investigators want to see if in pediatric patients, giving Zofran prior to propofol, reduces the pain that patients often experience when propofol is injected through an IV. Subjects will be randomized to 1 of 2 groups: lidocaine (common standard of care), or Zofran. The investigators hope to show a means of improving pain control in their patients undergoing anesthesia.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Propofol is a drug commonly used at the beginning of anesthesia (induction). Patients often experience discomfort when propofol is injected through an IV. Ondansetron (Zofran) is a drug that is commonly used to treat nausea after anesthesia. In adult studies, it has been shown that there is significantly less pain when Zofran is given just before propofol is given. The investigators want to see if giving Zofran prior to propofol reduces the pain and discomfort experienced by pediatric patients.

This study is a randomized, single-site clinical trial that will take place at Children's Healthcare of Atlanta at Egleston. Subjects will be randomized to 1 of 2 groups: lidocaine (common standard of care), or Zofran. During induction the treating anesthesiologist will be blinded to the study arm, however they will be unblinded at the end of induction. All subjects will receive Zofran at some point during the surgery - for patients not in the Zofran arm, they will receive it at the end of the case as usual. A blinded observer will score the subject's pain during propofol injection and vital signs will be recorded.

Subjects will be identified by the study team from the surgery schedule. Patients ages 2-17 undergoing surgery with peripheral vascular access (an IV) will be approached. Consent and assent (when appropriate) will be obtained. Subjects will not be compensated. Participation will consist only of the single duration of the surgery.

In this study the investigators hope to show a means of improving pain control in their patients undergoing anesthesia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ondansetron premedication Group

The ondansetron group will receive ondansetron 0.15mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.

Drug: Ondansetron
Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
Other Names:
  • Zofran, Ondansetron hydrochloride
  • Active Comparator: Lidocaine premedication Group

    The lidocaine group will receive lidocaine 2% 1mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.

    Drug: Lidocaine
    Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
    Other Names:
  • Xylocaine, lidocaine hydrochloride (HCl) Injection
  • Outcome Measures

    Primary Outcome Measures

    1. Change in verbal rating scale (VRS) form baseline [Baseline, during propofol injection (30 seconds)]

      Difference in total VRS between the lidocaine and ondansetron groups. Possible score ranges from 0 to 3 with higher scores correlating with worse pain.

    2. Change in Motor score scale from baseline [Baseline, during propofol injection (30 seconds)]

      Change in Motor score between the lidocaine and ondansetron groups. Possible score ranges from 0 to 3 with higher scores correlating with worse pain.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Years to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients 2 years old through 17 years of age

    • Children undergoing surgery at Children's Healthcare of Atlanta Egleston location

    • Patient with existing peripheral vascular access in the arm below the antecubital fossa

    • Patients with an American Society of Anesthesiologists (ASA) physical status category score of 1, 2 or 3

    • Parent or legal guardian willing to participate, and able to understand and sign the provided informed consent

    • No known chronic pain syndrome

    Exclusion Criteria:
    • Parent or legal guardian unwilling to participate or unable to understand and sign the provided informed consent

    • Patients presenting for endoscopy procedures

    • Known chronic pain syndrome

    • Patient diagnosed with long QT syndrome

    • Patient weighing >40kg

    • Documented allergy to study medications

    • Pain on injection of pre-operative normal saline flush

    • Patient has received an opioid within 30 minutes prior to anesthesia induction

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Children's Healthcare of Atlanta Atlanta Georgia United States 30322

    Sponsors and Collaborators

    • Emory University

    Investigators

    • Principal Investigator: Vipin Bansal, MD, Emory University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    VBansal, Assistant Professor, Emory University
    ClinicalTrials.gov Identifier:
    NCT05378113
    Other Study ID Numbers:
    • STUDY00001599
    First Posted:
    May 18, 2022
    Last Update Posted:
    Jul 14, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by VBansal, Assistant Professor, Emory University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 14, 2022